Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma.

CONCLUSION: PXN plays as an oncogene in glioma progression and suggests a new potential biotarget for therapy. PMID: 27637748 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27637748?dopt=Abstract

Source: CNS Neuroscience and Therapeutics - September 16, 2016 Category: Neuroscience Authors: Sun LH, Yang FQ, Zhang CB, Wu YP, Liang JS, Jin S, Wang Z, Wang HJ, Bao ZS, Yang ZX, Jiang T Tags: CNS Neurosci Ther Source Type: research